Dr. Ashish Jha on Covid-19: The Omicron Variant and the Outlook for 2022

From Delta to Omicron, and the outlook for 2022. Click "Show more" to view chapters. For more conversations, visit

Chapter 1 (00:15 - 31:06): Delta and Omicron

Chapter 2 (31:06 - 1:07:53): Outlook for 2022

Where do things stand with Covid-19? How has the emergence of the Omicron variant changed the situation? What can we expect in the short term and throughout 2022? To discuss these questions, we are joined again by Dr. Ashish Jha, dean of the Brown University School of Public Health. While noting that much still remains unknown about the Omicron variant, Jha suggests that the United States likely will be in for a challenging few months: "We have a lot of data that Omicron is going to spread very rapidly. But that doesn’t answer the question as to whether it’s more contagious inherently, or is it evading our immune response. It’s probably a combination of both. There is now pretty clear data that our vaccines will be pushed to the wall on this.” The good news, according to Jha, is our vaccines—especially taken with booster doses—likely will maintain strong protection against hospitalization and serious illness. The bad news is there still are a relatively large number of unvaccinated Americans who are particularly vulnerable. While explaining the situation, Jha also shares his perspective on the public policy and public health choices we have faced in recent months. Jha reflects on what he views as significant failures of the government, particularly the pace of the rollout of boosters and rapid tests. Finally, Jha and Kristol discuss possible paths forward in 2022 and what data we should keep our eyes on from the UK and the rest of the globe.